Your session is about to expire
← Back to Search
AZD5305 + Darolutamide for Prostate Cancer (ASCERTAIN Trial)
ASCERTAIN Trial Summary
This trial studies the effectiveness of two drugs alone or in combination to treat prostate cancer before surgery.
ASCERTAIN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ASCERTAIN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have heart or blood vessel problems, including recent heart attacks or strokes.I do not have severe illnesses or infections like HepB, hepatitis C, or HIV.I have a bleeding disorder or a history of blood cancer.I haven't had any other cancer that could affect this study's safety or results in the last 3 years.I am not taking any medications that affect my heart's rhythm.I tested positive for HCV antibody but my PCR test for HCV RNA is negative.I am a man older than 18.My organs and bone marrow are working well.I have prostate cancer at a high risk level and am eligible for surgery.I can sign and understand the consent form.My heart's electrical activity is within normal limits.I am not taking any strong medication or supplements that affect liver enzymes, and I can follow the study schedule.I have signed and agreed to provide my genetic information for research.I am considered a good candidate for major prostate surgery.
- Group 1: Saruparib (AZD5305) + Darolutamide
- Group 2: Saruparib (AZD5305) only
- Group 3: No Treatment
- Group 4: Darolutamide Only
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still slots available for individuals to participate in this experiment?
"Per clinicaltrials.gov, this investigation has ceased recruiting new patients since its last update on July 3rd 2023. Though the trial is not actively enrolling at present, 1324 other studies are currently accepting participants."
How widely distributed is this research endeavor?
"At this time, there are seven sites offering enrolment in the trial. These include Québec, Barcelona and Madrid along with other nearby locations. To decrease any onus related to travel for participants, it is advised that one selects a site closest them."
What risks are associated with AZD5305 treatment?
"Our Power team assigned AZD5305 a score of 1 since it is in its preliminary stage. This means that there is little evidence supporting the drug's safety and efficacy."
Share this study with friends
Copy Link
Messenger